Disc Medicine, Inc. (IRON)
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Disc Medicine, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 44.39M shares outstanding
USBased in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company.
Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases.
The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Leadership
Donald Nicholson, Ph.D.
Executive Chairman and Director
Georges Gemayel, Ph.D.
Director
Jean Franchi
Chief Financial Officer
John Quisel, J.D., Ph.D.
Director, President and Chief Executive Officer; President, Chief Executive Officer and Director
Employees
165
Country
US
Sector
Healthcare
Website
discmedicine.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Bitterman Kevin | Director | Sale | 11.5K | $920.2K | Oct 21, 2026 |
| Bitterman Kevin | Director | Sale | 266 | $21.3K | Oct 21, 2026 |
| Bitterman Kevin | Director | Sale | 13.8K | $1.11M | Oct 21, 2026 |
| Bitterman Kevin | Director | Sale | 2.4K | $190.9K | Oct 20, 2026 |
| Bitterman Kevin | Director | Sale | 2.9K | $229.4K | Oct 20, 2026 |
| Bitterman Kevin | Director | Sale | 55 | $4.4K | Oct 20, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
FMR LLC | 4.9M | 11.0% | 13F |
FMR LLC · also on 13F· joint filing· may incl. warrants· filed Aug 2026 | 4.9M | 11.0% | 13G |
AI DMI LLC · may incl. warrants· filed Oct 2025 | 3.0M | 6.8% | 13D |
BlackRock, Inc. | 2.5M | 5.6% | 13F |
RA CAPITAL MANAGEMENT, L.P. | 2.5M | 5.5% | 13F |
RA Capital Management, L.P. · also on 13F· may incl. warrants· filed Jan 2026 | 2.2M | 5.0% | 13G |
JPMORGAN CHASE & CO | 1.9M | 4.2% | 13F |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.9M | 4.2% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Nov 2024 | 1.9M | 4.2% | 13G |
WELLINGTON MANAGEMENT GROUP LLP | 1.7M | 3.9% | 13F |
Insiders
- Bitterman KevinDirector
- Quisel John DChief Executive Officer
- Yu Jonathan Yen-WenChief Operating Officer
- Khara RahulChief Legal Officer
- White William RichardDirector
- Ratcliffe LiamDirector
- AHMED NADIMDirector
- Chin MarkDirector
- GEMAYEL GEORGESDirector
- Nicholson Donald WilliamDirector
based on 44.39M shares outstanding
US30d Avg
1.46M
60d Avg
997.12K
90d Avg
769.89K